Potent and selective oxindole-based vasopressin 1b receptor antagonists with improved pharmacokinetic properties

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 12, 2011, Pages 3828-3831

  Oost, Thorsten ^a   Backfisch, Gisela ^a   Bhowmik, Swati ^a   Van Gaalen, Marcel M ^a   Geneste, Hervé ^a   Hornberger, Wilfried ^a   Lubisch, Wilfried ^a   Netz, Astrid ^a   Unger, Liliane ^a   Wernet, Wolfgang ^a  

^a ABBOTT GMBH AND CO KG   (Germany)

Author keywords

Metabolic stability; Oxindole; SSR149415; V1b; Vasopressin 1b

Indexed keywords

NELIVAPTAN; OXINDOLE; VASOPRESSIN V1B RECEPTOR;

AREA UNDER THE CURVE; ARTICLE; DEPRESSION; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; NONHUMAN; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; DISEASE MODELS, ANIMAL; INDOLES; MOLECULAR STRUCTURE; PROTEIN BINDING; RATS; RECEPTORS, VASOPRESSIN;

RATTUS;

EID: 79957868761     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.03.012     Document Type: Article

References (15)

1. (a) Serradeil-Le Gal, C.; Wagnon, J.; Simiand, J.; Griebel, G.; Lacour, C.; Guillon, G.; Barberis, C.; Brossard, G.; Soubrie, P.; Nisato, D.; Pascal, M.; Pruss, R.; Scatton, B.; Maffrand, J.-P.; Le Fur, G. J. Pharmacol. Exp. Ther. 2002, 300, 1122;
2. (b) Griebel, G.; Simiand, J.; Serradeil-Le Gal, C.; Wagnon, J.; Pascal, M.; Scatton, B.; Maffrand, J.-P.; Soubrie, P. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 6370.
3. According to information on nelivaptan from thomson-pharma.com (search performed on December 3, 2010)
4. (a) Hodgson, R. A.; Higgins, G. A.; Guthrie, D. H.; Lu, S. X.; Pond, A. J.; Mullins, D. E.; Guzzi, M. F.; Parker, E. M.; Varty, G. B. Pharmacol., Biochem. Behav. 2007, 3, 431;
5. (b) Kumagai, T.; Kuwada, T.; Shibata, T.; Hayashi, M.; Fujisawa, Y.; Sekiguchi, Y. EP 1659121, 2006.;
6. (c) Schönberger, M.; Leggett, C.; Kim, S. W.; Hooker, J. M. Bioorg. Med. Chem. Lett. 2010, 20, 3103.
7. Nassar, A.-E. F.; Kamel, A. M.; Clarimont, C. Drug Discovery Today 2004, 9, 1020.
8. (a) Mongin, F.; Queguiner, G. Tetrahedron 2001, 57, 4059;
9. (b) Turck, A.; Ple, N.; Mongin, F.; Queguiner, G. Tetrahedron 2001, 57, 4489.
10. (a) Tahara, A.; Saito, M.; Sugimoto, T.; Tomura, Y.; Wada, K.; Kusayama, T.; Tsukada, J.; Ishii, N.; Yatsu, T.; Uchida, W.; Tanaka, A. Br. J. Pharmacol. 1998, 125, 1463;
11. (b) Strakova, Z.; Kumar, A.; Watson, A. J.; Soloff, M. S. Mol. Pharmacol. 1997, 51, 217;
12. (c) Jasper, J. R.; Harrell, C. M.; O'Brien, J. A.; Pettibone, D. J. Life Sci. 1995, 57, 2253.
13. Obach, S. Drug Metab. Dispos. 1999, 27, 1350.
14. Jacobs, J.; Jain, R. K.; Lewis, J. G.; Patel, D. V.; Yuan, Z. US 2003/0069223, 2003.
15. Porsolt, R. D.; Le Pichon, M.; Jalfre, M. Nature 1977, 266, 730.